Previous 10 | Next 10 |
Snap (SNAP) -30% as it warns on EBITDA, revenues, deteriorating economy; social media peers tumble. BigBear.ai Holdings (BBAI) -26%. Abercrombie & Fitch (ANF) -25% on Q1 earnings release. GeoVax Labs (GOVX) -22% after Moderna enters monkeypox vaccine developm...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Catalyst Biosciences (NASDAQ: CBIO ) stock is jumping on the sale of its protease medicines portfolio. Vertex Pharmaceuticals (NASDAQ: VRTX ) is buying it for $60 million. This is part of Catalyst Bioscienc...
Leerink has initiated Vertex Pharmaceuticals (NASDAQ:VRTX) with a market perform rating saying that the biotech needs to validate its pipeline and pursue more M&A to diversify. The firm has a $265 price target (~2% upside based on Friday's close). Analyst David Risinger said that while gr...
Penny stocks are shares of companies that trade for less than $5. While some people may have their own definitions, this is generally considered the standard. Whatever the case, the goals are the same: make money and repeat the process. One of the most exciting things about finding chea...
The clinical-stage biotech Catalyst Biosciences (NASDAQ:CBIO) announced on Monday that cystic fibrosis drugmaker, Vertex Pharmaceuticals (VRTX) signed an asset purchase and sale agreement with the company to acquire a group of product candidates for $60 million in cash. Nano-cap Catalyst Bio ...
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s...
Catalyst Biosciences press release (NASDAQ:CBIO): Q1 GAAP EPS of -$0.46 misses by $0.02. Revenue of $0.8M (-45.6% Y/Y). Cash and cash equivalents as of March 31, 2022, were $34.8 million. Shares -4.99% PM. For further details see: Catalyst Biosciences GAAP EPS of -$0.46 misses by $0.02,...
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader pr...
Catalyst Biosciences press release (NASDAQ:CBIO): FY GAAP EPS of -$2.87 misses by $0.01. Revenue of $7.34M (-65.0% Y/Y) beats by $2.19M. Shares +3% PM. For further details see: Catalyst Biosciences GAAP EPS of -$2.87 misses by $0.01, revenue of $7.34M beats by $2.19M
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “In late 2021 we announced a st...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Biosciences Inc. Company Name:
CBIO Stock Symbol:
NASDAQ Market:
Catalyst Biosciences Inc. Website:
The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) (“...
Catalyst Biosciences Inc. (CBIO) is expected to report $-0.05 for Q3 2023
NEW YORK, NY / ACCESSWIRE / March 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Broadmark Realty Capital Inc. (NYS...